5-甲基-3-(1,2,3,6-四氢-吡啶-4-基)-1H-吲哚 | 460354-14-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 5-甲基-3-(1,2,3,6-四氢-吡啶-4-基)-1H-吲哚
• 英文名称: 5-methyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole
• CAS: 460354-14-7
• 化学式: C₁₄H₁₆N₂
• 分子量: 212.29
• InChiKey: OMZNYPYIJITEIM-UHFFFAOYSA-N

物化性质

• 沸点：
  412.0±45.0 °C(Predicted)
• 密度：
  1.137±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  27.8
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  [(2R)-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinolin-2-yl]methyl 4-methylbenzenesulfonate 、 5-甲基-3-(1,2,3,6-四氢-吡啶-4-基)-1H-吲哚 在 氮气 、 乙酸乙酯 、 碳酸氢钠 、 Brine 、 magnesium sulfate 、 silica gel 、 异丙醇 、 富马酸 、 monofumarate 作用下， 以 二甲基亚砜 为溶剂， 反应 6.0h， 以to give 0.32 g of the (S)-enantiomer of the title compound as a yellow solid monofumarate, three-quarter hydrate (m.p. 150-155° C.)的产率得到2-[4-(5-Methyl-1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1-ylmethyl]-8-methyl-2,3-dihydro[1,4]dioxino[2,3-f]quinoline
  参考文献：
  名称：

  ANTIDEPRESSANT AZAHETEROCYCLYMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO[2,3-F]QUINOLINE

  摘要：

  公式为1的化合物对于治疗抑郁症（包括但不限于重度抑郁障碍、儿童抑郁症和慢性抑郁症）、焦虑症、恐慌症、创伤后应激障碍、经前期症候群（也称为经前综合征）、注意力缺陷障碍（有和没有多动症）、强迫症、社交焦虑障碍、广泛性焦虑障碍、肥胖症、进食障碍如厌食症、贪食症、血管运动性潮红、可卡因和酒精成瘾、性功能障碍及相关疾病方面具有用途。

  公开号：

  US20020165245A1

文献信息

• HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER
  申请人：Asana Biosciences, LLC

  公开号：US20160362407A1

  公开（公告）日：2016-12-15

  The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful for inhibiting ERK1/2. By administering to a patient in need a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, Z, J, M, and R 1 to R 8 are defined herein, these compounds are effective in treating conditions associated with dysregulation of the RAS/RAF/MEK/ERK pathway. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.

  本申请提供了新颖的杂环化合物及其药用可接受的盐。还提供了制备这些化合物的方法。这些化合物对抑制ERK1/2有用。通过向需要治疗的患者施用式(I)的一个或多个化合物的治疗有效量，其中X、Y、Z、J、M和R1至R8在此处定义，这些化合物在治疗与RAS/RAF/MEK/ERK通路失调相关的疾病方面是有效的。可以使用这些化合物治疗各种疾病，包括以异常细胞增殖为特征的疾病。在一个实施例中，该疾病是癌症。
• Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoline
  申请人：Wyeth

  公开号：US20030045542A1

  公开（公告）日：2003-03-06

  Compounds of the formula: 1 are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa, bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.

  公式为1的化合物可用于治疗抑郁症（包括但不限于重度抑郁障碍、儿童抑郁症和心境恶劣障碍）、焦虑症、恐慌症、创伤后应激障碍、经前期不良情绪障碍（也称经前综合征）、注意力缺陷障碍（伴有或不伴有多动症）、强迫症、社交焦虑障碍、广泛性焦虑障碍、肥胖症、进食障碍如厌食症、贪食症、潮红、可卡因和酒精成瘾、性功能障碍及相关疾病的治疗。
• Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxinol[2,3f]quinoline
  申请人：Wyeth

  公开号：US06599915B2

  公开（公告）日：2003-07-29

  Compounds of the formula: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa, bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.

  公式为的化合物：对于治疗抑郁症（包括但不限于重度抑郁障碍、儿童抑郁症和慢性抑郁症）、焦虑症、惊恐障碍、创伤后应激障碍、经前期不良情绪障碍（也称经前综合征）、注意力缺陷障碍（有和无过动症）、强迫症、社交焦虑障碍、广泛性焦虑障碍、肥胖症、饮食障碍如厌食症、贪食症、血管运动性潮红、可卡因和酒精成瘾、性功能障碍及相关疾病方面有用。
• Antidepressant azaheterocyclymethyl derivatives of 2,3-dihydro-1,4-dioxino [2,3-f]quinoline
  申请人：Wyeth

  公开号：US06458802B1

  公开（公告）日：2002-10-01

  Compounds of the formula: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders such as anorexia nervosa, bulimia nervosa, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.

  该公式的化合物对于治疗抑郁症（包括但不限于重度抑郁障碍、儿童抑郁症和慢性低落情绪）、焦虑症、惊恐障碍、创伤后应激障碍、经前期不适障碍（也称为经前综合征）、注意力缺陷障碍（伴有或不伴有多动症）、强迫症、社交焦虑障碍、广泛性焦虑障碍、肥胖症、进食障碍如厌食症、贪食症、潮红、可卡因和酒精成瘾、性功能障碍及相关疾病具有治疗作用。
• ANTIDEPRESSANT AZAHETEROCYCLYMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO 2,3-F]QUINOLINE
  申请人：Wyeth

  公开号：EP1392697B1

  公开（公告）日：2004-11-03